Cellinta Limited

Cellinta Limited is a pioneering force in biotechnology research, dedicated to targeting cancer stem cells through highly selective gene therapy. Leveraging deep expertise in stem cell biology, synthetic biology, and molecular genetics, Cellinta Limited has developed a cutting-edge platform for identifying cancer stem cell-specific regulatory circuits. This innovative approach enables the highly selective delivery of anti-cancer payloads, simultaneously disrupting multiple pathways essential for tumor growth while stimulating robust immune responses.

With a focus on addressing the unmet needs in various solid tumors, Cellinta Limited is actively building a robust pipeline of therapeutics. The company's primary address is 71 Kingsway, London, WC2B 6ST, GB. Cellinta Limited’s commitment to innovation and precision medicine is reinforced by its backing from SV Health Investors, a leading transatlantic life sciences and healthcare investor with over $3 billion in capital commitments, and capital from the Impact Medicine Fund.

Cellinta Limited is poised to make significant advancements in cancer treatment. We invite the management of Cellinta Limited to create a customized and exclusive company showcase and product listing on our platform, providing an enhanced avenue to share your groundbreaking work with the world.